Comprehensive product portfolio

Our finished oncology dosage products portfolio comprises of over 40 formulations. They include cost-effective cytotoxic and cytostatic drugs in intravenous dose forms which are of highest quality and still cost competitive. The possibility of combining several medications to provide advanced combination therapy to cancer patients makes it an attractive proposition for institutional buyers. A focused strategy is in place to strengthen our portfolio consistently by monitoring and analyzing potential patent expirations.

Cost competitiveness

Being cost-efficient is a pre-requisite in the highly competitive market for oncology generic products. We have a competitive edge which can be attributed to the vertical integration of our business operations right from bulk activities to finished formulations.

Speed to market

Innovative and successful launches at the proper time and in the right markets to produce the right results is a major determinant for any high-achieving generic product. Success heavily depends on a Company’s agility and ability to launch a product at patent expiry and duly assuring that the launch routes are steep and sustained. At Fresenius Kabi Oncology Limited, we ensure speed to market through our technically talented regulatory team, ensuring pre-patent expiry registrations, our competency to develop key products through non-infringing processes and by leveraging the vast global distribution network of our Company. 

Research & Development

Research and development are widely acknowledged as the cornerstones of scientific advancements, and the level of proficiency is a trustworthy indication of the potential to innovate. We have a dedicated team of highly qualified scientists engaged in developing the second wave of products, including the creation of next-generation cytotoxic, cytostatic, and targeted therapies for care of cancer patients. 

Strong network

Just as profitability is the primary focus of the attractiveness for a Company in an industry, an important secondary factor is the position of that Company within that industry. To maintain the leading position in the cancer generics segment, we have built dependable and economical marketing and distribution systems in every region of the globe. The distribution of our products through our broad sales and marketing network will accelerate the global roll-out of our generic cancer care product portfolio.